Who owns OCUPHIRE PHARMA INC?
- Ticker: IRD
- CUSIP Number: 67577r102
Tip: Access positions for across all investors
Analyze quarterly positions in Ocuphire Pharma with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Ocuphire Pharma stock
Who bought or sold OCUPHIRE PHARMA INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Caligan Partners | 6.1M | $28M | 100% | Mar 2026 |
|
| Adage Capital Partners GP | 6.0M | $27M | 446% | Mar 2026 |
|
| BIOS Capital Management | 3.7M | $17M | 0% | Mar 2026 |
|
| Balyasny Asset Management | 2.7M | $12M | 0% | Mar 2026 |
|
| Millennium Management | 2.6M | $12M | 31% | Mar 2026 |
|
| Vanguard Capital Management | 2.4M | $11M | 100% | Mar 2026 |
|
| Marshall Wace | 2.3M | $11M | 1367% | Mar 2026 |
|
| Boxer Capital Management | 2.3M | $10M | 100% | Mar 2026 |
|
| ADAR1 Capital Management | 1.8M | $8.4M | 4523% | Mar 2026 |
|
| Perceptive Advisors | 1.8M | $8.4M | -58% | Mar 2026 |
|
| Nantahala Capital Management | 1.7M | $7.7M | -65% | Mar 2026 |
|
| Woodline Partners | 1.4M | $6.2M | 100% | Mar 2026 |
|
| Boothbay Fund Management | 1.2M | $5.4M | 100% | Mar 2026 |
|
| Opaleye Management | 1.1M | $2.3M | 0% | Mar 2026 |
|
| Farallon Capital Management | 1.0M | $4.6M | 100% | Mar 2026 |
|
| Susquehanna International | 905k | $4.1M | 265% | Mar 2026 |
|
| Bleichroeder | 737k | $3.4M | 0% | Mar 2026 |
|
| Mink Brook Asset Management | 591k | $2.7M | -65% | Mar 2026 |
|
| Geode Capital Management | 538k | $2.5M | 7% | Mar 2026 |
|
| Trails Edge Capital Partners | 500k | $2.3M | 100% | Mar 2026 |
|
| Ameriprise Financial | 389k | $1.8M | 100% | Mar 2026 |
|
| Goldman Sachs Group | 327k | $1.5M | 100% | Mar 2026 |
|
| Dr. Jeffrey R. Jay, M.D. | 324k | $1.5M | 100% | Mar 2026 |
|
| Vanguard Fiduciary Trust | 282k | $1.3M | 100% | Mar 2026 |
|
| UBS Group | 258k | $1.2M | 187% | Mar 2026 |
|
| Jane Street | 202k | $917k | 100% | Mar 2026 |
|
| State Street Corporation | 200k | $910k | 15% | Mar 2026 |
|
| BlackRock | 148k | $672k | 4% | Mar 2026 |
|
| Voleon Capital Management | 144k | $654k | 100% | Mar 2026 |
|
| Seven Fleet Capital Management | 134k | $611k | 100% | Mar 2026 |
|
| Creative Planning | 128k | $584k | 0% | Mar 2026 |
|
| Citadel Advisors | 121k | $550k | -33% | Mar 2026 |
|
| Two Sigma Investments | 109k | $494k | -28% | Mar 2026 |
|
| Northern Trust | 94k | $430k | 8% | Mar 2026 |
|
| Texas Capital Bank Wealth Management Services | 89k | $403k | 13% | Mar 2026 |
|
| Simplex Trading | 83k | $375k | 810% | Mar 2026 |
|
| Renaissance Technologies | 73k | $333k | -42% | Mar 2026 |
|
| Stonepine Capital Management | 69k | $313k | 100% | Mar 2026 |
|
| Regency Capital Management | 68k | $309k | 48% | Mar 2026 |
|
| Hrt Financial | 68k | $307k | 100% | Mar 2026 |
|
| Bank of America Corporation | 67k | $305k | 100% | Mar 2026 |
|
| Palogic Value Management | 65k | $296k | 100% | Mar 2026 |
|
| Brevan Howard Capital Management | 61k | $279k | 100% | Mar 2026 |
|
| Empowered Funds | 42k | $191k | 0% | Mar 2026 |
|
| Bridgeway Capital Management | 42k | $191k | 0% | Mar 2026 |
|
| Mangrove Partners | 42k | $190k | 100% | Mar 2026 |
|
| OMERS Administration Corporation | 42k | $189k | -53% | Mar 2026 |
|
| Morgan Stanley | 40k | $180k | 38% | Mar 2026 |
|
| Charles Schwab Investment Management | 35k | $159k | 100% | Mar 2026 |
|
| Captrust Financial Advisors | 32k | $146k | 0% | Mar 2026 |
|
| Tower Research Capital | 29k | $131k | 100% | Mar 2026 |
|
| nVerses Capital | 29k | $130k | 100% | Mar 2026 |
|
| Vanguard Global Advisers | 22k | $101k | 100% | Mar 2026 |
|
| Miller Financial Services | 22k | $100k | 120% | Mar 2026 |
|
| Raymond James Financial | 20k | $89k | -5% | Mar 2026 |
|
| Persistent Asset Partners | 18k | $82k | 100% | Mar 2026 |
|
| XTX Topco | 17k | $76k | -30% | Mar 2026 |
|
| James Investment Research | 16k | $75k | 0% | Mar 2026 |
|
| Goss Wealth Management | 16k | $75k | 0% | Mar 2026 |
|
| Bedel Financial Consulting | 15k | $68k | 0% | Mar 2026 |
|
| Kestra Private Wealth Services | 13k | $58k | -20% | Mar 2026 |
|
| William Blair $ Company | 13k | $57k | -55% | Mar 2026 |
|
| Stokes Family Office | 12k | $55k | 0% | Mar 2026 |
|
| First City Capital Management | 12k | $54k | 0% | Mar 2026 |
|
| Group One Trading | 11k | $48k | 100% | Mar 2026 |
|
| Reliant Investment Partners | 10k | $46k | 0% | Mar 2026 |
|
| Annandale Capital | 10k | $46k | 0% | Mar 2026 |
|
| Hilton Head Capital Partners | 4.5k | $20k | 100% | Mar 2026 |
|
| Wells Fargo & Company | 3.8k | $17k | -98% | Mar 2026 |
|
| Farther Finance Advisors | 3.5k | $14k | 52% | Jun 2026 |
|
| Advisor Group Holdings | 2.2k | $10k | -84% | Mar 2026 |
|
| National Bank Of Canada /fi/ | 2.0k | $9.1k | 0% | Mar 2026 |
|
| Barclays | 1.9k | $8.6k | 0% | Mar 2026 |
|
| SBI Securities | 530.00 | $2.4k | -79% | Mar 2026 |
|
| International Assets Investment Management | 521.00 | $2.4k | 0% | Mar 2026 |
|
| FMR | 8.00 | $36.000000 | 100% | Mar 2026 |
|
| Royal Bank of Canada | 5.00 | $0 | 100% | Mar 2026 |
|
| Hanson McClain Advisors | 5.00 | $23.000000 | 0% | Mar 2026 |
|
Who sold out of Ocuphire Pharma?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Voss Capital | Dec 2025 | 442k | $888k |
| Qube Research & Technologies | Dec 2025 | 40k | $80k |
| Johnson Investment Counsel | Dec 2025 | 20k | $40k |
| Virtu Financial | Dec 2025 | 17k | $34k |
| Occudo Quantitative Strategies | Dec 2025 | 12k | $25k |
| Sanders Morris Harris | Mar 2026 | 12k | $55k |